On Jan. 8, 2020, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
Read the FDA announcement.
Posted 1/8/2020
On Day 2 of the 2026 NCCN Fall Policy Summit, speakers and panelists discussed the greatest operational hurdles preventing personalized cancer screening, offered proven best practices in five real-world case studies, and explored policy solutions to modernize screening systems.
